Therapeutic effect of sodium oligomannate combined with donepezil on Alzheimer disease and its influence on cognitive function
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
目的 分析甘露特钠联合多奈哌齐治疗阿尔茨海默病的效果及对患者认知功能的影响。 方法 随机对照研究。抽取2021年1月至2023年3月新乡医学院第一附属医院收治的阿尔茨海默病患者56例，按随机数字表法分为观察组和对照组，每组28例。对照组采用多奈哌齐治疗，观察组在对照组基础上给予甘露特钠治疗。比较两组治疗效果、认知功能评分[简易精神状态检查表(MMSE)、阿尔茨海默病评定量表-认知量表(ADAS-cog)]、精神行为症状评分[Cohen-Mansfield激越问卷(CMAI)、痴呆行为评定量表(BRSD)]、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)]水平、肠道菌群代谢标志物[苯丙氨酸(Phe)、短链脂肪酸(SCFA)]、脑脊液生物标志物[β-内啡肽(β-EP)、亮氨酸-脑啡肽(LEK)]。 结果 观察组治疗总有效率(96.43%，27/28)与对照组(82.14%，23/28)比较差异未见统计学意义(P>0.05)。治疗后，观察组MMSE评分高于对照组，ADAS-cog评分低于对照组(P<0.05)。治疗后，观察组CMAI、BRSD评分低于对照组(P<0.05)。治疗后，观察组TNF-α、IL-6水平低于对照组，IL-10水平高于对照组(P<0.05)。治疗后，观察组Phe低于对照组，SCFA高于对照组(P<0.05)。治疗后，观察组β-EP水平高于对照组，LEK水平低于对照组(P<0.05)。 结论 甘露特钠治疗阿尔茨海默病患者，可调节脑脊液生物标志物和肠道菌群代谢标志物表达，减轻炎症反应，改善认知功能和精神行为症状，临床效果显著。 Objective To analyze the effects of sodium oligomannate combined with donepezil in the treatment of Alzheimer disease, and its influence on cognitive function. Methods This study was a randomized controlled trail. Fifty-six patients with Alzheimer disease treated in the First Affiliated Hospital of Xinxiang Medical University from January 2021 to March 2023 were selected, and they were divided into observation group and control group according to the random number table method, with 28 cases in each group. The control group was treated with donepezil, and the observation group was treated with sodium oligomannate based on the treatment of the control group. The efficacy, cognitive function scores evaluated by mini-mental state examination (MMSE) and Alzheimer disease assessment scale-cognitive (ADAS-cog), mental and behavioral symptoms scores assessed by the Cohen-Mansfield agitation inventory (CMAI) and behavior rating scale of dementia (BRSD), levels of inflammatory factors, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10), intestinal flora metabolic markers, including phenylalanine (Phe) and short chain fatty acids (SCFA), and cerebrospinal fluid biomarkers, including β-endorphin (β-EP) and leucine enkephalin (LEK), were compared between the two groups. Results There was no significant difference in the total effective rate between the observation group (96.43%, 27/28) and the control group (82.14%, 23/28), P>0.05. After treatment, the MMSE score of the observation group was higher than that of the control group, and the ADAS-cog score was lower than that of the control group (P<0.05). After treatment, the scores of CMAI and BRSD of the observation group were lower than those of the control group (P<0.05). After treatment, the levels of TNF-α and IL-6 in the observation group were lower than those in the control group, and the level of IL-10 was higher than that in the control group (P<0.05). After treatment, the observation group had lower Phe and higher SCFA, compared with the control group (P<0.05). After treatment, the observation group had higher level of β-EP and lower level of LEK, compared with the control group (P<0.05). Conclusions Sodium oligomannate in the treatment of Alzheimer disease can regulate the expression of cerebrospinal fluid biomarkers and intestinal flora metabolic markers, reduce inflammatory response, improve cognitive function and mental and behavioral symptoms, of which the clinical effect is significant.
Objective To analyze the effects of sodium oligomannate combined with donepezil in the treatment of Alzheimer disease, and its influence on cognitive function. Methods This study was a randomized controlled trail. Fifty-six patients with Alzheimer disease treated in the First Affiliated Hospital of Xinxiang Medical University from January 2021 to March 2023 were selected, and they were divided into observation group and control group according to the random number table method, with 28 cases in each group. The control group was treated with donepezil, and the observation group was treated with sodium oligomannate based on the treatment of the control group. The efficacy, cognitive function scores evaluated by mini-mental state examination (MMSE) and Alzheimer disease assessment scale-cognitive (ADAS-cog), mental and behavioral symptoms scores assessed by the Cohen-Mansfield agitation inventory (CMAI) and behavior rating scale of dementia (BRSD), levels of inflammatory factors, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10), intestinal flora metabolic markers, including phenylalanine (Phe) and short chain fatty acids (SCFA), and cerebrospinal fluid biomarkers, including β-endorphin (β-EP) and leucine enkephalin (LEK), were compared between the two groups. Results There was no significant difference in the total effective rate between the observation group (96.43%, 27/28) and the control group (82.14%, 23/28), P>0.05. After treatment, the MMSE score of the observation group was higher than that of the control group, and the ADAS-cog score was lower than that of the control group (P<0.05). After treatment, the scores of CMAI and BRSD of the observation group were lower than those of the control group (P<0.05). After treatment, the levels of TNF-α and IL-6 in the observation group were lower than those in the control group, and the level of IL-10 was higher than that in the control group (P<0.05). After treatment, the observation group had lower Phe and higher SCFA, compared with the control group (P<0.05). After treatment, the observation group had higher level of β-EP and lower level of LEK, compared with the control group (P<0.05). Conclusions Sodium oligomannate in the treatment of Alzheimer disease can regulate the expression of cerebrospinal fluid biomarkers and intestinal flora metabolic markers, reduce inflammatory response, improve cognitive function and mental and behavioral symptoms, of which the clinical effect is significant.
万方数据
